Table 3 The final B-cell epitopes for the MEV construction
From: Design of a novel multi-epitope vaccine against Marburg virus using immunoinformatics studies
Sequence | Protein | Start position | Score | Antigenicity | Allergenicity |
|---|---|---|---|---|---|
VGLQCSPCLMSKATST | VP35 | 43 | 0.92 | 1.04 | NON-ALLERGEN |
MASSSNYNTYMQYLNP | VP40 | 1 | 0.95 | 0.52 | NON-ALLERGEN |
IIDISAYNERTVKGVP | VP40 | 66 | 0.93 | 0.91 | NON-ALLERGEN |
TVKKQAYRQHKNPNNG | VP40 | 208 | 0.91 | 0.50 | NON-ALLERGEN |
DGLINAPIDFDPVPNT | GP | 449 | 0.98 | 0.64 | NON-ALLERGEN |
GPGIEGLYTAGLIKNQ | GP | 537 | 0.91 | 0.45 | NON-ALLERGEN |
QGYRHMNLTSTNKYWT | GP | 184 | 0.90 | 1.02 | NON-ALLERGEN |
QGIKTLPILEIASNNQ | GP | 14 | 0.90 | 0.57 | NON-ALLERGEN |